Travere Therapeutics/$TVTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Travere Therapeutics
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
Ticker
$TVTX
Sector
Primary listing
Employees
385
Headquarters
Website
TVTX Metrics
BasicAdvanced
$2.3B
-
-$2.00
0.79
-
Price and volume
Market cap
$2.3B
Beta
0.79
52-week high
$28.69
52-week low
$12.91
Average daily volume
2.6M
Financial strength
Current ratio
2.003
Quick ratio
1.898
Long term debt to equity
992.885
Total debt to equity
1,220.182
Interest coverage (TTM)
-15.11%
Profitability
EBITDA (TTM)
-120.539
Gross margin (TTM)
2.92%
Net profit margin (TTM)
-50.64%
Operating margin (TTM)
-51.12%
Effective tax rate (TTM)
0.06%
Revenue per employee (TTM)
$870,000
Management effectiveness
Return on assets (TTM)
-19.28%
Return on equity (TTM)
-705.73%
Valuation
Price to revenue (TTM)
6.618
Price to book
71.1
Price to tangible book (TTM)
-31.96
Price to free cash flow (TTM)
-14.046
Free cash flow yield (TTM)
-7.12%
Free cash flow per share (TTM)
-1.86
Growth
Revenue change (TTM)
87.94%
Earnings per share change (TTM)
5.34%
3-year revenue growth (CAGR)
23.44%
10-year revenue growth (CAGR)
17.98%
3-year earnings per share growth (CAGR)
-18.51%
10-year earnings per share growth (CAGR)
5.60%
What the Analysts think about TVTX
Analyst ratings (Buy, Hold, Sell) for Travere Therapeutics stock.
Bulls say / Bears say
Travere’s Q2 2025 product sales surged 82% year-over-year to $94.8 million, driven by a 165% increase in U.S. sparsentan sales to $71.9 million, demonstrating robust IgAN market adoption (Reuters )
The FDA approved an update to sparsentan’s REMS, reducing liver‐function monitoring from monthly to quarterly and removing embryo-fetal toxicity requirements, simplifying prescribing and broadening patient access (Bloomberg)
Wall Street’s median 12-month price target for Travere is $30, implying approximately 44% upside, reflecting strong analyst confidence in the company’s growth trajectory (Reuters )
Despite a 119% revenue increase in Q2 2025 to $114.4 million, Travere reported a GAAP net loss of $12.8 million, highlighting ongoing unprofitability amid its growth phase (Reuters )
Q2 2025 operating expenses totaled $127.1 million—exceeding revenues of $114.4 million—underscoring margin pressure from elevated R&D and SG&A investments (Reuters )
Travere’s supplemental NDA for sparsentan in FSGS carries a PDUFA date of January 13, 2026, delaying potential market expansion and associated revenue streams (Reuters )
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2025.
TVTX Financial Performance
Revenues and expenses
TVTX Earnings Performance
Company profitability
TVTX News
AllArticlesVideos
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
Business Wire2 weeks ago
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire4 weeks ago
Why Top 4% Stock, Travere Therapeutics, Skyrocketed To A Three-Year High
Investors Business Daily4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Travere Therapeutics stock?
Travere Therapeutics (TVTX) has a market cap of $2.3B as of October 07, 2025.
What is the P/E ratio for Travere Therapeutics stock?
The price to earnings (P/E) ratio for Travere Therapeutics (TVTX) stock is 0 as of October 07, 2025.
Does Travere Therapeutics stock pay dividends?
No, Travere Therapeutics (TVTX) stock does not pay dividends to its shareholders as of October 07, 2025.
When is the next Travere Therapeutics dividend payment date?
Travere Therapeutics (TVTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Travere Therapeutics?
Travere Therapeutics (TVTX) has a beta rating of 0.79. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.